Sugi Predict

Sugi Predict / Compounds / SCHEMBL18980644

SCHEMBL18980644

SCHEMBL18980644

CCOC(=O)C=C1C2CC1CN(Cc1ccccc1)C2

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
▸ L3MBTL1 Q9Y468 2/20 0.44
▸ ATM Q13315 1/20 0.44
▸ S1PR1 P21453 1/20 0.44
▸ S1PR5 Q9H228 1/20 0.44
▸ MAPK1 P28482 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ ALDH1A1 P00352 1/20 0.43
▸ MEN1 O00255 1/20 0.43
▸ KMT2A Q03164 1/20 0.43
▸ MAPT P10636 1/20 0.42
▸ FUCA1 P04066 2/20 0.42
▸ CYP3A4 P08684 1/20 0.42
▸ CYP2D6 P10635 1/20 0.42
▸ CYP2C9 P11712 1/20 0.42
▸ CYP2C19 P33261 1/20 0.42
▸ SIGMAR1 Q99720 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16519954 0.92 L3MBTL1 (0.46) L3MBTL1ATMS1PR1S1PR5MAPK1
SCHEMBL23567005 0.87 S1PR5 (0.46) S1PR1S1PR5LMNAMEN1KMT2A
SCHEMBL19000151 0.84 S1PR5 (0.50) L3MBTL1S1PR1S1PR5LMNAALDH1A1
SCHEMBL30329104 0.83 SMN1; SMN2 (0.46) L3MBTL1MEN1KMT2ACYP2C19
SCHEMBL20399875 0.79 S1PR5 (0.46) S1PR1S1PR5KMT2AFUCA1SIGMAR1
SCHEMBL28662028 0.77 S1PR5 (0.44) S1PR1S1PR5ALDH1A1FUCA1
SCHEMBL4579407 0.76 KMT2A (0.56) MAPK1LMNAALDH1A1MEN1KMT2A
SCHEMBL8539224 0.76 MEN1 (0.47) L3MBTL1ATMMAPK1LMNAALDH1A1
SCHEMBL8539225 0.76 MEN1 (0.47) L3MBTL1ATMMAPK1LMNAALDH1A1
SCHEMBL25324118 0.76 LMNA (0.41) L3MBTL1ATMS1PR1S1PR5MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2025-02-20 — — US disclosed
US-20240067633-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-02-29 — — US disclosed
US-20240067633-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF XIZANG HAISCO PHARMACEUTICAL CO., LTD. (CN) 2024-02-29 — — US disclosed
EP-4269404-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF Sichuan Haisco Pharmaceutical Co., Ltd. (CN) 2023-11-01 — — EP disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2023-09-28 — — US disclosed
CN-116635377-A Ketohexokinase inhibitors and uses thereof 四川海思科制药有限公司 2023-08-22 — — CN disclosed
US-11629134-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2023-04-18 — — US disclosed
WO-2022135390-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF 四川海思科制药有限公司 2022-06-30 — — WO disclosed
EP-3889146-A1 POLYHETEROCYCLIC TLR7/8 ANTAGONISTS AND THEIR USES FOR TREATING IMMUNE DISORDERS Merck Patent GmbH (DE) 2021-10-06 — — EP disclosed
US-10544122-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2020-01-28 — — US disclosed
US-20190330183-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-10-31 — — US disclosed
US-20190330183-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2019-10-31 — — US disclosed
US-10399957-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2019-09-03 — — US disclosed
US-10399957-B2 TLR7/8 antagonists and uses thereof MERCK PATENT GMBH (DE) 2019-09-03 — — US disclosed
EP-3390389-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS Merck Patent GmbH (DE) 2018-10-24 — — EP disclosed
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-06-22 — — US disclosed
WO-2017106607-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS MERCK PATENT GMBH (DE) 2017-06-22 — — WO disclosed
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF MERCK PATENT GMBH (DE) 2017-06-22 — — US disclosed
WO-2017106607-A1 POLYCYCLIC TLR7/8 ANTAGONISTS AND USE THEREOF IN THE TREATMENT OF IMMUNE DISORDERS MERCK PATENT GMBH (DE) 2017-06-22 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230303514-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 L3MBTL1 2469/4885ATM 807/4885S1PR1 850/4885
US-20190330183-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 L3MBTL1 2469/4885ATM 807/4885S1PR1 850/4885
US-11629134-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 L3MBTL1 2469/4885ATM 807/4885S1PR1 850/4885
US-10544122-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 L3MBTL1 2469/4885ATM 807/4885S1PR1 850/4885
US-20250059157-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 L3MBTL1 2469/4885ATM 807/4885S1PR1 850/4885
US-10399957-B2 TLR7/8 antagonists and uses thereof TLR7, TLR8, TLR9 L3MBTL1 3637/4885ATM 1235/4885S1PR1 652/4885
US-20170174653-A1 TLR7/8 ANTAGONISTS AND USES THEREOF TLR7, TLR8, TLR9 L3MBTL1 3637/4885ATM 1235/4885S1PR1 652/4885
US-20240067633-A1 KETOHEXOKINASE INHIBITOR AND USE THEREOF KHK, GCK, HK1 L3MBTL1 2979/4885ATM 3848/4885S1PR1 1618/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.